IMAG

HF

CSE

CANSCMR

CNCT

Workshop

IMAGING IN CARDIAC AMYLOIDOSIS, WHAT THE CARDIOLOGIST SHOULD KNOW. JOINT SESSION CSE/CANSCMR/CNCT

Chair(s)

• Nowell F.

  Nowell Fine, MD SM PRCPC

  Director of Echocardiography, Heart Failure Cardiologist
  Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary
  University of Calgary

Co-Chair(s)

• 

  Davinder Jassal, MD, FACC, FRCPC

  Professor
  CCS and CSE
  University of Manitoba

Presenter(s)

• 

  Francois Tournoux, MD PhD

  Assistant Professor
  CHUM
  Université de Montréal
• Sarah B.

  Sarah Blissett

  Cardiologist
  University of California
• 

  Gary Small, MB, BCh, BSc, PhD, MRCP

  Associate Professor
  University of Ottawa Heart Institute
• 

  Margot Davis, MD SM FRCPC

  Assistant Professor

With the development of new therapeutics in cardiac amyloidosis, interest has signficantly increased in this disease which was considered until very recently as incurable. However, although a few recent reports suggest that the incidence of the disease is higher than initially thought, its diagnosis remains problematic. While definite diagnosis is made through cardiac biopsy, non invasive imaging is the first tool to screen patients and raise the diagnosis.

This workshop endorsed by the Canadian Society of Echocardiography includes participation from the Canadian Society of Cardiovascular Magnetic Resonance and the Canadian Nuclear and CT Imaging community.

The suggested titles are:
- echo: when to suspect the diagnosis - Francois Tournoux
- cardiac MRI: additional value for the diagnosis - Sarah Blissett
- nuclear imaging: why and when to order it? - Gary Small
- Follow-up and prognosis of cardiac amyloidosis: what are the key imaging parameters? - Margot Davis

 

Learning Objectives

At the conclusion of this session, participants will be able to:

• know when to suspect the diagnosis of amyloidosis from an echocardiogram;
• understand the additional value of cardiac MRI and nuclear imaging for the diagnosis of cardiac amyloidosis; and
• identify the key imaging parameters used for the follow-up of patients with cardiac amyloidosis.